Quarterly Results | Eli Lilly and Company
The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
Lilly provides update on 2024 revenue guidance, announces 2025 …
4 days ago · For Q4 2024, Lilly now expects worldwide revenue to be approximately $13.5 billion, representing growth of 45% compared to Q4 2023. This includes approximately $3.5 billion for Mounjaro ® and $1.9 billion for Zepbound ®. In addition to the uptake of Mounjaro and Zepbound, Lilly saw strong performance from its oncology, immunology and ...
Q4 2024 Earnings Call | Eli Lilly and Company
The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5.5 Billion …
4 days ago · Eli Lilly expects fourth-quarter 2024 revenue of approximately $13.5 billion, representing a 45% year-over-year growth compared to the consensus of $13.97 billion. ... Eli Lilly Cuts Q4 Revenue ...
Eli Lilly Cuts Q4 Sales Forecast: ETFs to Buy on the Dip - Yahoo …
3 days ago · Eli Lilly also cut its revenue guidance for full-year 2024 to $45 billion from the previous expectation of $45.4-$46 billion. The new outlook still indicates 32% year-over-year growth in revenues.
Lilly Cuts Q4 Revenue View Below Market, Lifts FY24 Outlook; …
4 days ago · Lilly now expects approximately $3.5 billion for Mounjaro and $1.9 billion for Zepbound. In total, non-incretin revenue grew by 20 percent. However, the company's expected 2024 revenue is about 3 ...
Eli Lilly Cuts Q4 Forecast Amid Weak Sales but Sees Bright 2025 …
4 days ago · Eli Lilly revises Q4 revenue down on slower U.S. incretin market growth, eyes robust 2025 projections. ... Eli Lilly voiced hope for its long-term performance. The company expects income for ...
Eli Lilly's Q4 2024 Earnings: What to Expect - Nasdaq
5 days ago · Analysts expect Eli Lilly’s EPS to climb 107.9% to $13.14 in fiscal 2024, up from $6.32 in 2023. In fiscal 2025, EPS is projected to increase by 82.9% annually to $24.03.
Eli Lilly's Q4 2024 Earnings: What to Expect - Barchart.com
5 days ago · Eli Lilly is scheduled to release its Q4 earnings report next month, and analysts forecast triple-digit profit growth. ... Eli Lilly and Company: Most Popular News. 1. Legendary Investor Michael Burry Is Betting on This ‘Strong Buy’ Stock for 2025. 2.
Eli Lilly issues Q4 2024 revenue guidance below consensus
4 days ago · Eli Lilly and Company (NYSE:LLY) announced on Tuesday that the pharmaceuticals company expects Q4 2024 revenue to be ~$13.5B. The consensus revenue estimate stands at $13.95B. "While the U.S ...